Active, not recruitingPhase 1NCT05694598
Safety and Tolerability of VGR-R01 for Patients With Bietti Crystalline Dystrophy
Studying Bietti crystalline dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Shanghai Vitalgen BioPharma Co., Ltd.
- Principal Investigator
- Wenbin WeiBeijing Tongren Hospital
- Intervention
- VGR-R01(genetic)
- Enrollment
- 12 enrolled
- Eligibility
- 18-69 years · All sexes
- Timeline
- 2023 – 2028
Study locations (1)
- Shanghai Vitalgen Biopharma Co.,Ltd., Shanghai, Shanghai Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05694598 on ClinicalTrials.govOther trials for Bietti crystalline dystrophy
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNANCT07307469Compassionate Administration of ZVS101e Injection for Extended TreatmentChigenovo Co., Ltd
- RECRUITINGPHASE3NCT06743646Efficacy and Safety of ZVS101e in Patients With Bietti 's Crystalline DystrophyChigenovo Co., Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT06699108Study to Evaluate the Efficacy and Safety of VGR-R01 Gene Therapy in Patients With Bietti Crystalline DystrophyShanghai Vitalgen BioPharma Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06706427Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy SubjectsNGGT (Suzhou) Biotechnology Co., Ltd.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT06302608Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal DystrophyXiamen Ophthalmology Center Affiliated to Xiamen University